Intra-patient heterogeneity of BRAF mutation status: fact or fiction?

by Menzies, A M, Wilmott, J S, Long, G V, Scolyer, R A
Published 2014

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

by Hu, W, Jin, L, Jiang, C C, Long, G V, Scolyer, R A, Wu, Q, Zhang, X D, Mei, Y, Wu, M
Published 2013

BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma

by Wilmott, J S, Menzies, A M, Haydu, L E, Capper, D, Preusser, M, Zhang, Y E, Thompson, J F, Kefford, R F, von Deimling, A, Scolyer, R A, Long, G V
Published 2013

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma

by Carlino, M S, Haydu, L E, Kakavand, H, Menzies, A M, Hamilton, A L, Yu, B, Ng, C C, Cooper, W A, Thompson, J F, Kefford, R F, O'Toole, S A, Scolyer, R A, Long, G V
Published 2014